These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 29184980)

  • 1. Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinoma.
    Chen L; Huang CF; Li YC; Deng WW; Mao L; Wu L; Zhang WF; Zhang L; Sun ZJ
    Cell Mol Life Sci; 2018 Jun; 75(11):2045-2058. PubMed ID: 29184980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NLRP3 inflammasome activation promotes inflammation-induced carcinogenesis in head and neck squamous cell carcinoma.
    Huang CF; Chen L; Li YC; Wu L; Yu GT; Zhang WF; Sun ZJ
    J Exp Clin Cancer Res; 2017 Sep; 36(1):116. PubMed ID: 28865486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer.
    Liu JF; Wu L; Yang LL; Deng WW; Mao L; Wu H; Zhang WF; Sun ZJ
    J Exp Clin Cancer Res; 2018 Mar; 37(1):44. PubMed ID: 29506555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NLRP3 in tumor-associated macrophages predicts a poor prognosis and promotes tumor growth in head and neck squamous cell carcinoma.
    Chen L; Wan SC; Mao L; Huang CF; Bu LL; Sun ZJ
    Cancer Immunol Immunother; 2023 Jun; 72(6):1647-1660. PubMed ID: 36586012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. γ-Secretase inhibitor reduces immunosuppressive cells and enhances tumour immunity in head and neck squamous cell carcinoma.
    Mao L; Zhao ZL; Yu GT; Wu L; Deng WW; Li YC; Liu JF; Bu LL; Liu B; Kulkarni AB; Zhang WF; Zhang L; Sun ZJ
    Int J Cancer; 2018 Mar; 142(5):999-1009. PubMed ID: 29047105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion.
    Tengesdal IW; Menon DR; Osborne DG; Neff CP; Powers NE; Gamboni F; Mauro AG; D'Alessandro A; Stefanoni D; Henen MA; Mills TS; De Graaf DM; Azam T; Vogeli B; Palmer BE; Pietras EM; DeGregori J; Tan AC; Joosten LAB; Fujita M; Dinarello CA; Marchetti C
    Proc Natl Acad Sci U S A; 2021 Mar; 118(10):. PubMed ID: 33649199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer.
    Liu JF; Ma SR; Mao L; Bu LL; Yu GT; Li YC; Huang CF; Deng WW; Kulkarni AB; Zhang WF; Sun ZJ
    Mol Oncol; 2017 Feb; 11(2):235-247. PubMed ID: 28102051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nlrp3 Inflammasome Inhibitor MCC950 Ameliorates Obliterative Bronchiolitis by Inhibiting Th1/Th17 Response and Promoting Treg Response After Orthotopic Tracheal Transplantation in Mice.
    Xu KY; Tong S; Wu CY; Ding XC; Chen JL; Ming Y; Wang SH
    Transplantation; 2020 Jun; 104(6):e151-e163. PubMed ID: 32108749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of adenosine A2A receptor enhances CD8
    Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells.
    Younis RH; Han KL; Webb TJ
    J Immunol; 2016 Feb; 196(3):1419-29. PubMed ID: 26740106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.
    Wu L; Mao L; Liu JF; Chen L; Yu GT; Yang LL; Wu H; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Cancer Immunol Res; 2019 Oct; 7(10):1700-1713. PubMed ID: 31387897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of interleukin-13 receptor α2 for treatment of head and neck squamous cell carcinoma induced by conditional deletion of TGF-β and PTEN signaling.
    Hall B; Nakashima H; Sun ZJ; Sato Y; Bian Y; Husain SR; Puri RK; Kulkarni AB
    J Transl Med; 2013 Feb; 11():45. PubMed ID: 23421960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
    Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
    J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The inflammasome component NLRP3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells.
    van Deventer HW; Burgents JE; Wu QP; Woodford RM; Brickey WJ; Allen IC; McElvania-Tekippe E; Serody JS; Ting JP
    Cancer Res; 2010 Dec; 70(24):10161-9. PubMed ID: 21159638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tr1 Cells, but Not Foxp3+ Regulatory T Cells, Suppress NLRP3 Inflammasome Activation via an IL-10-Dependent Mechanism.
    Yao Y; Vent-Schmidt J; McGeough MD; Wong M; Hoffman HM; Steiner TS; Levings MK
    J Immunol; 2015 Jul; 195(2):488-97. PubMed ID: 26056255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma.
    Weed DT; Vella JL; Reis IM; De la Fuente AC; Gomez C; Sargi Z; Nazarian R; Califano J; Borrello I; Serafini P
    Clin Cancer Res; 2015 Jan; 21(1):39-48. PubMed ID: 25320361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TIM3/CEACAM1 pathway involves in myeloid-derived suppressor cells induced CD8
    Yu S; Ren X; Meng F; Guo X; Tao J; Zhang W; Liu Z; Fu R; Li L
    Immunology; 2023 Feb; 168(2):273-289. PubMed ID: 35470423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gegen Qinlian decoction ameliorates TNBS-induced ulcerative colitis by regulating Th2/Th1 and Tregs/Th17 cells balance, inhibiting NLRP3 inflammasome activation and reshaping gut microbiota.
    Hu Y; Tang J; Xie Y; Xu W; Zhu W; Xia L; Fang J; Yu D; Liu J; Zheng Z; Zhou Q; Shou Q; Zhang W
    J Ethnopharmacol; 2024 Jun; 328():117956. PubMed ID: 38428658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of MCP-1/CCR4 signaling-induced recruitment of activated regulatory cells evokes an antitumor immune response in head and neck squamous cell carcinoma.
    Sun W; Li WJ; Wei FQ; Wong TS; Lei WB; Zhu XL; Li J; Wen WP
    Oncotarget; 2016 Jun; 7(25):37714-37727. PubMed ID: 27177223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma.
    Yu GT; Mao L; Wu L; Deng WW; Bu LL; Liu JF; Chen L; Yang LL; Wu H; Zhang WF; Sun ZJ
    Cell Mol Life Sci; 2018 Nov; 75(22):4223-4234. PubMed ID: 29955905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.